Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CyberKnife Dose Escalation for Unfavorable and High-risk Prostate Cancer

NCT03822494 is registered in ClinicalTrials.gov with Crozer-Keystone Health System as lead sponsor.

NCT NCT03822494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03822494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CyberKnife Dose Escalation for Unfavorable and High-risk Prostate Cancer
Lead sponsor
Crozer-Keystone Health System
Phase
Not applicable
Overall status
Active, not recruiting
Start date
July 12, 2018
Completion date
July 12, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, prostate cancer, prostate neoplasm